Health Law Alliance (HLA) is proud to share that our very own Diana Yastrovskaya was recently featured in a discussion on Pharmacy Benefit Managers (PBMs) for WJAC. In this segment, Diana offered her insights into the complex and often misunderstood role that PBMs play in the healthcare system.
The discussion centered on the impact of PBMs on local pharmacies, the breadth of PBM power, and the challenges this creates for independent businesses. Diana explained how PBMs act as intermediaries between insurers, pharmacies, and drug manufacturers, and how their practices can have significant implications for both patients and providers. She emphasized the importance of transparency in PBM operations and stressed that greater clarity could lead to more affordable and accessible medications for consumers.
Importantly, Diana shared how she works directly with independent pharmacies to help them push back against unfair PBM practices. Through her expertise in healthcare law and regulatory frameworks, she advocates for policies that empower smaller pharmacies to compete on a more level playing field.
Her participation in the WJAC discussion reflects HLA’s ongoing commitment to advancing critical conversations around healthcare law, policy, and practice. By breaking down complex industry dynamics and providing actionable guidance, Diana continues to champion fairness, efficiency, and patient well-being.
MORE ARTICLES BY CATEGORY
By Appointment Only: How DME Suppliers Can Prevent Unexpected DME License Revocations
DME suppliers can prevent unexpected and costly license revocations by strategically applying with a "By Appointment Only" designation. This article explores the common compliance trap of failing unannounced site visits due to conflicts between standard pharmacy operating hours and Medicare's "posted hours" requirement for DME suppliers. "By Appointment Only" status is a crucial safeguard, which suppliers can take to implement to protect their DME billing privileges.
Read More >>Resolving Prescription “Red Flags” Is No Longer Optional: Federal Scrutiny Tightens on Controlled-Substance Dispensing
Pharmacists must resolve “red flags” under the Controlled Substances Act’s corresponding-responsibility requirements before dispensing controlled substances. Overlooking warning signs, such as cash-paid, high-dose opioid prescriptions—can now trigger False Claims Act liability and massive penalties, as demonstrated by Walgreens’ $350 million settlement in April 2025.
Read More >>9th Circuit’s Landmark EKRA Ruling—What Providers Should Know
On July 11, 2025, the 9th Circuit upheld a laboratory operator’s convictions for violating EKRA by paying marketing agents to mislead providers into providing patient referrals for medically unnecessary blood tests. In this article, we analyze the 9th Circuit’s ruling and what it means for the future of EKRA enforcement.
Read More >>Collateral Consequences Mount Quickly After Adverse DEA Inspection
Adverse findings during a DEA inspection can trigger a chain reaction of serious consequences for pharmacies, including increasing fines, suspension or revocation of DEA registrations and pharmacy licenses, costly False Claims Act (FCA) lawsuits, and potential criminal liability.
Read More >>
